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Abstract: Patients with Graves’ orbitopathy have a higher probability of myasthenia gravis 
than does the normal population. Overlapping clinical features cause diagnostic confusion in 
such a situation. We herein report a patient with Graves’ orbitopathy and myasthenia gravis 
(GO-MG) with normal left eyelid height, but in whom upper eyelid retraction was shown after 
edrophonium chloride administration. Upper eyelid retraction in GO-MG is occasionally masked 
by a myasthenia effect. The upper eyelid height must be carefully monitored in patients with 
Graves’ orbitopathy to detect the presence of concomitant myasthenia gravis.
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Introduction
Patients with Graves’ orbitopathy have a higher probability of myasthenia gravis than 
the normal population.1 According to a large retrospective case series, myasthenia 
gravis was diagnosed in two of 150 patients with Graves’ orbitopathy (1.3%).2 Patients 
with Graves’ orbitopathy commonly show eyelid retraction and/or hypotropia and/or 
esotropia, as well as exophthalmos, lagophthalmos, exposure keratopathy, and less 
frequently, compressive optic neuropathy.3 However, patients with myasthenia gravis 
often demonstrate ptosis and/or exotropia, but a consistent pattern of eye movement 
disturbances is usually not present.3 Upper eyelid retraction in Graves’ orbitopathy 
and myasthenia gravis (GO-MG) is frequently camouflaged, and these patients may 
show a normal upper eyelid height. We herein report a patient with GO-MG with 
left normal eyelid height, but in whom the upper eyelid retraction was disclosed 
after edrophonium chloride administration.
Case report
A 46-year-old man with Graves’ disease, well controlled by thiamazole 5 mg/day, 
was referred to our clinic to treat his Graves’ orbitopathy. Although both eyes had 
exophthalmos (20 mm OD, 19 mm OS; normal range, ,17 mm)4, he demonstrated a 
normal left eyelid height and right ptosis, ie, margin reflex distance-1, 3.5 mm OS and 
0.5 mm OD, respectively (Figure 1). His primary eye position was exotropic, dominantly 
on his right side, and the upward gaze of the right eye was severely restricted (Figure 2). 
Coronal computed tomography of the orbits showed bilateral enlargement of the inferior 
rectus muscle, medial rectus muscle, superior oblique muscle, and superior rectus 
muscle-levator muscle complex (Figure 3A). Axial computed tomography demonstrated 
bilateral medial and lateral recti muscle enlargement (Figure 3B). Localization of these 
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Figure 1 Patient photograph before edrophonium chloride administration.
Figure 2 Patient’s eye positions in nine directions of gaze before edrophonium 
chloride administration.
Figure 3A Coronal computed tomography of the orbits shows bilateral enlargement 
of the inferior rectus muscle, medial rectus muscle, superior oblique muscle, and 
superior rectus muscle-levator muscle complex.
Figure 3B Axial computed tomography demonstrates bilateral medial and lateral 
recti muscle enlargement.
muscle involvements did not match the characteristics of the 
eye movement disorder (Figure 3C).
Because the aforementioned findings raised suspicion 
for the presence of both Graves’ orbitopathy and myasthenia 
gravis, we performed an edrophonium chloride test.5 The 
margin reflex distance-1 had improved to 2.5 mm OD and 
8.0 mm OS (Figure 4), although the eye movement had not 
clearly improved.
Some days later, the result of a serum acetylcholine 
receptor antibody assay was positive (1.8 nmol/L; 
normal, ,0.2 nmol/L). Because the patient could completely 
close his left eye, we prescribed pyridostigmine bromide 
180 mg/day,5 and the eyelid height stabilized. The exophthal-
mos did not change after the administration of pyridostigmine 
bromide.
Comment
The association between Graves’ orbitopathy and myasthenia 
gravis has long been recognized.2,6 Although it is not difficult 
to differentiate clinically between simple Graves’ orbitopathy 
and myasthenia gravis, overlapping clinical features, such 
as upper eyelid height and/or eye movement disturbances 
occasionally cause diagnostic confusion, especially in 
patients with normal thyroid function.
The most frequent sign of Graves’ orbitopathy is upper 
eyelid retraction,7 which is caused by overaction of the 
Müller’s muscle because of excess catecholamines and 
cicatricial contraction of the levator muscles after the inflam-
matory process.7 For the overaction, topical guanethidine 
therapy is sometimes effective.8 For the contraction, steroid 
administration and botulinum toxin injection are indicated 
during the active phase, and surgical correction is necessary 
in the static phase.7
Graves’ orbitopathy also shows eye movement disturbances, 
which have a restrictive myopathy pattern.3 The inferior and 
medial rectus muscles are frequently involved, and imaging 
discloses their hypertrophy when in the active phase.
On the other hand, ptosis and diplopia are present in about 
90% of patients with myasthenia gravis, and these ocular 
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symptoms are an initial complaint in 20% of patients with 
myasthenia gravis.9–11 Muscle hypertrophy does not exist on 
imaging in myasthenia gravis.12 No particular predilection 
of extraocular muscle involvement is shown in myasthenia 
gravis. However, solitary paresis usually occurs, in the form 
of an adduction deficit resulting in exotropia, which was the 
case in the present patient. Exotropia is more common in 
ocular myasthenia gravis.3
In spite of the obvious differences between Graves’ 
orbitopathy and myasthenia gravis, each condition shares 
several features, potentially making it difficult to reach a 
correct diagnosis. Upper eyelid ptosis, typically suggestive 
of myasthenia gravis, may be seen with Graves’ orbitopathy 
as a result of levator myopathy,13 apical compression,14,15 
and pseudoptosis secondary to upper eyelid retraction in 
the fellow eye.16 However, if ptosis develops in a patient 
with Graves’ orbitopathy, simultaneous myasthenia gravis 
should be considered,17 although ocular myasthenia gravis 
with orbital pain may imply orbital inflammation.18
In our patient, the right ptosis and exotropia suggested 
concomitant myasthenia gravis, which motivated us to 
perform an edrophonium chloride test. The left upper 
eyelid, appearing to have a normal height, was retracted 
to margin reflex distance-1 8.0 mm, and the right side, 
regarded as ptosis, moved to margin reflex distance-1 2.5 mm 
(Figure 4). This examination demonstrated that the left upper 
eyelid originally had an upper eyelid retraction that was 
camouflaged by the ocular myasthenia gravis.
Treatment of our patient was complicated because of 
laterality and strabismus induced by myasthenia gravis. 
When the eyelid height stabilizes after medication with 
improvement of strabismus, a sling surgery may be 
performed on the right upper eyelid. However, if strabismus 
persists, this strategy must be abandoned. When left upper 
eyelid retraction is conspicuous with lagophthalmos, left 
upper eyelid lengthening surgery may be performed.19
In conclusion, upper eyelid retraction in patients with 
GO-MG may be camouflaged by a myasthenia effect. The 
upper eyelid height must be carefully monitored in patients 
with Graves’ orbitopathy to detect the presence of concomi-
tant myasthenia gravis.
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Figure 3C Hess screen chart before edrophonium chloride administration.
Figure 4 After edrophonium chloride administration.
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